Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: Results of a retrospective database analysis

Clinical Therapeutics

Volumn 28, Issue 6, 2006, Pages 979-989

  Fu, Alex Z ^a   Christensen, Dale B ^b   Hansen, Richard A ^b   Liu, Gordon G ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

bipolar depression; bipolar disorder; depressive relapse; propensity score; second generation antidepressant

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ADULT; ANALYTIC METHOD; ARTICLE; BIPOLAR DEPRESSION; CONFIDENCE INTERVAL; DATA BASE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PROPORTIONAL HAZARDS MODEL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT REFUSAL;

EID: 33745934285     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.06.011     Document Type: Article

References (31)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 Suppl 4 (2002) 1-50
2. Thase M.E., and Sachs G.S. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiatry 48 (2000) 558-572
3. Ghaemi S.N., Lenox M.S., and Baldessarini R.J. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 62 (2001) 565-569
4. Calabrese J.R., Rapport D.J., Shelton M.D., et al. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 38 (1998) 185-191
5. Frances A.J., Kahn D.A., Carpenter D., et al. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 59 Suppl 4 (1998) S73-S79
6. Spec No:1-104. Sachs G.S., Printz D.J., Kahn D.A., et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med. (2000)
7. Prien R.F., Kupfer D.J., Mansky P.A., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41 (1984) 1096-1104
8. Altshuler L., Kiriakos L., Calcagno J., et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: A retrospective chart review. J Clin Psychiatry 62 (2001) 612-616
9. Altshuler L., Suppes T., Black D., et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160 (2003) 1252-1262
10. International Classification of Diseases, Ninth Revision, Clinical Modification. 3rd ed (1989), US Dept of Health and Human Services, Public Health Service, Health Care Financing Administration, Washington, DC
11. Goodwin F.K., Fireman B., Simon G.E., et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290 (2003) 1467-1473
12. Frankle W.G., Perlis R.H., Deckersbach T., et al. Bipolar depression: Relationship between episode length and antidepressant treatment. Psychol Med 32 (2002) 1417-1423
13. Fu A.Z., Krishnan A.A., Harris S.D., and Thompson T.R. The economic burden of bipolar-related phases of depression versus mania phases. Drug Benefit Trends 16 (2004) 569-575
14. Andersen R.M. Revisiting the behavioral model and access to medical care: Does it matter?. J Health Soc Behav 36 (1995) 1-10
15. Charlson M.E., Pompei P., Ales K.L., and McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
16. D'Hoore W., Bouckaert A., and Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 49 (1996) 1429-1433
17. Cassidy F., Ahearn E., and Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156 (1999) 1417-1420
18. Spearing M.K., Post R.M., Leverich G.S., et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res 73 (1997) 159-171
19. Rosenbaum P.R., and Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
20. Ghaemi S.N., Sachs G.S., Chiou A.M., et al. Is bipolar disorder still under-diagnosed? Are antidepressants overutiIized?. J Affect Disord 52 (1999) 135-144
21. Suppes T., Leverich G.S., Keck P.E., et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 67 (2001) 45-59
22. Shin K., Schaffer A., Levitt A.J., and Boyle M.H. Seasonality in a community sample of bipolar, unipolar and control subjects. J Affect Disord 86 (2005) 19-25
23. Kim C.D., Lesage A.D., Seguin M., et al. Seasonal differences in psychopathology of male suicide completers. Compr Psychiatry 45 (2004) 333-339
24. Thompson A., Hunt C., and Issakidis C. Why wait? Reasons for delay and prompts to seek help for mental health problems in an Australian clinical sample. Soc Psychiatry Psychiatr Epidemiol 39 (2004) 810-817
25. Sims A. The scar that is more than skin deep: The stigma of depression. Br J Gen Pract 43 (1993) 30-31
26. Eaddy M., Bramley T., and Regan T. Time to antidepressant discontinuation: A comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manage Care Interface 16 (2003) 22-27
27. Crown W.H., Finkelstein S., Berndt E.R., et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63 (2002) 963-971
28. Schulman K.A., Yabroff K.R., Kong J., et al. A claims data approach to defining an episode of care. Health Serv Res 34 (1999) 603-621
29. Goodwin F.K., and Jamison K.R. Manic-Depressive Illness (1990), Oxford University Press, New York, NY
30. Andrews J.M., Ninan P.T., and Nemeroff C.B. Venlafaxine: A novel antidepressant that has a dual mechanism of action. Depression 4 (1996) 48-56
31. Buchanan T.M., and Ramadan N.M. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol 26 (2006) 188-198